Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Published:2016-12 Issue:12 Volume:17 Page:1661-1671
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Neal Joel W,Dahlberg Suzanne E,Wakelee Heather A,Aisner Seena C,Bowden Michaela,Huang Ying,Carbone David P,Gerstner Gregory J,Lerner Rachel E,Rubin Jerome L,Owonikoko Taofeek K,Stella Philip J,Steen Preston D,Khalid Ahmed Ali,Ramalingam Suresh S

Funder

National Cancer Institute of the National Institutes of Health under the following award numbers:

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment;International Journal of Molecular Sciences;2024-08-22

2. Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials;Medicine;2024-07-05

3. Synthesis, Anticancer Activity, and Docking Studies of Novel Hydroquinone-Chalcone-Pyrazoline Hybrid Derivatives;International Journal of Molecular Sciences;2024-07-02

4. Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC);Cancer Pathogenesis and Therapy;2024-07

5. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11